30 closest matches · ranked by relevance
Astrocytoma, Grade III
Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Brain and Central Nervous System Tumors
Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
High Grade Glioma
Primary: Response Rate
Brain and Central Nervous System Tumors
Primary: Overall Survival Rate at 3 Years — 73.1 percentage of participants — p=<0.001
Malignant Glioma · Glioblastoma · Gliosarcoma
Primary: 6-month Progression-free Survival — 88.8 percentage of participants
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate — 22 percentage of participants
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Glioblastoma · Gliosarcoma
Primary: 12-month Progression Free Survival (PFS) — 43.8; 34.4 percentage of participants
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
Glioblastoma Multiforme/Anaplastic Astrocytoma
Primary: Maximum Tolerated Dose(MTD)of Temozolomide(TMZ) — 75 mg/m^2
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Glioblastoma Multiforme · Gliosarcoma
Primary: Radiographic Response — 27.8 percentage of participants
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
Adult Anaplastic Astrocytoma · Adult Giant Cell Glioblastoma · Adult Gliosarcoma
Primary: Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma — 0; 0; NA; 0 DLTs
Anaplastic Astrocytoma · Glioblastoma
Primary: Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse — 4; 2; 2 Participants
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Adult Anaplastic Astrocytoma · Adult Anaplastic Ependymoma · Adult Anaplastic Oligodendroglioma
Primary: Maximum Tolerated Dose (MTD) of Alisertib — 50 mg dose of Alisertib
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Gliomas
Primary: Overall Response Rate — 9 percent
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Glioma
Primary: Progression-free Survival
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Glioblastoma · Gliosarcoma
Primary: 6-month Progression-free Survival (PFS) — 25; 28.6 percentage of participants